Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.
Aerovate Therapeutics Price Performance
Shares of AVTE stock traded up $0.01 during trading on Tuesday, reaching $2.47. The company's stock had a trading volume of 7,592 shares, compared to its average volume of 578,953. The company has a market capitalization of $71.32 million, a price-to-earnings ratio of -0.83 and a beta of 1.01. Aerovate Therapeutics has a 1-year low of $1.25 and a 1-year high of $32.42. The stock's 50-day moving average price is $2.50 and its 200 day moving average price is $2.40.
Aerovate Therapeutics Company Profile
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Recommended Stories
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
